GADOTERIDOL

Post-LOE

gadoteridol

Bracco

ANDAINJECTIONINJECTABLE

Approved

Feb 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

GADOTERIDOL (gadoteridol) by Bracco is magnetic resonance contrast activity [moa]. Approved for paramagnetic contrast agent [epc]. First approved in 2025.

Drug data last refreshed 19h ago

See 1 job working on GADOTERIDOL →

Mechanism of Action

Magnetic Resonance Contrast Activity

Pharmacologic Class:

Paramagnetic Contrast Agent

Indications (1)

Paramagnetic Contrast Agent

Clinical Trials (1)

NCT00522951Phase 3Completed

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Started Aug 2007

165 enrolled

Brain Metastases

Why This Matters for Your Career

Worked on GADOTERIDOL at Bracco? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.